AbbVie's (ABBV) phase 3 trial data is compelling; however that doesn't guarantee it will win out over competitors Gilead (GILD) and Bristol-Myers (BMY)
If approved, empagliflozin from Eli Lilly and Boehringer Ingelheim Pharmaceuticals would compete against AstraZeneca's Forxiga and Johnson & Johnson's Invokana.
Amarin sues AstraZeneca over its fish oil pill Epanova. If the companies can't reach sales close to GlaxoSmithKline's Lovaza, it will be for naught.
Eli Lilly struggles to gain approval and regain diabetes market share.
New breakthrough designation could help Bristol-Myers compete more quickly with market-leader Gilead.
Roche, Regeneron, Cell Therapeutics, and AstraZeneca could all make health-care headlines this morning. Here's why.
February's over -- and investors of these horrendous health-care stocks of the week just might be saying "good riddance." Here's why.
Amarin has to diferentiate Vasecepa from GlaxoSmithKline's and AbbVie's drugs or cuts costs massively.
AstraZeneca has turned around its pipeline, but the Street has definitely noticed.
See what three competing HCV combos with breakthrough designations will do to Gilead's blockbuster.